Biologics such as vaccines, monoclonal antibodies and stem cells represent some of the most promising approaches to treat and cure so far intractable diseases and pathologies such as cancers, diabetes, ... The production of these medicines requires highly secure and controlled manufacturing process environments in which adventitious contaminations such viruses and bacteria are strictly forbidden from end-products for safety reasons.

The biopharma companies and Contract Manufacturing Organization (CMO) are actively looking for new and more robust (speed and sensitivity) diagnostics PCR-based tests for instance, to mitigate contaminations such as with Mycoplasma and viruses such as MVM (Minute Virus of Mouse) to comply with the tighter and tighter safety regulations.

Progenus proposes PCR and Next Generation Sequencing (NGS) -based services: